The global human chorionic gonadotropin market size was accounted for USD 2.15 billion in 2024, grew to USD 2.22 billion in 2025 and is projected to surpass around USD 2.94 billion by 2034, representing a CAGR of 3.20% between 2025 and 2034. The North America human chorionic gonadotropin market size is evaluated at USD 880 million in 2024 and is expected to grow at a CAGR of 3.24% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Human Chorionic Gonadotropin (HCG) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Human Chorionic Gonadotropin (HCG) Market Revenue and Volume, by Product Type, 2025-2034
8.1.1 Native Human Chorionic Gonadotropin
8.1.1.1. Market Revenue and Volume Forecast (2022-2034)
8.1.2. Recombinant Human Chorionic Gonadotropin
8.1.2.1. Market Revenue and Volume Forecast (2022-2034)
9.1. Human Chorionic Gonadotropin (HCG) Market Revenue and Volume, by Therapeutic Area, 2025-2034
9.1.1. Female Infertility Treatment
9.1.1.1. Market Revenue and Volume Forecast (2022-2034)
9.1.2. Male Hypogonadism
9.1.2.1. Market Revenue and Volume Forecast (2022-2034)
9.1.3. Oligospermic Treatment
9.1.3.1. Market Revenue and Volume Forecast (2022-2034)
9.1.4. Cryptorchidism Treatment
9.1.4.1. Market Revenue and Volume Forecast (2022-2034)
9.1.5. Chronic Pain
9.1.5.1. Market Revenue and Volume Forecast (2022-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Volume Forecast (2022-2034)
10.1. Human Chorionic Gonadotropin (HCG) Market Revenue and Volume, by Distribution Channel, 2025-2034
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2022-2034)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2022-2034)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Volume Forecast (2022-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.1.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.2.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product Type (2022-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2022-2034)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2022-2034)
12.1. Aspen API
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Livzon Pharmaceuticals
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Lupin
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck & Co., Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Scripps Laboratories
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Shanghai Techwell Biopharmaceutical Co. Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sun Pharmaceuticals Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Zydus Lifesciences Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck Serono
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Ningbo Renjian Pharmaceutical Group Co. Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample